We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Smartphone-Based Optical Imaging Offers Onsite Diagnostics

By LabMedica International staff writers
Posted on 08 Feb 2017
A novel smartphone-based optical imaging and molecular assay system permits on-site diagnostics and facilitates transfer of molecular diagnostic data from the point-of-care (POC) to the point-of-expertise, providing a cost-effective means for molecular diagnostics even in resource-limited settings.

The device, which can image and analyze specific DNA sequences and genetic mutations in tumor cells and tissue samples without prior DNA extraction, was developed through the collaborative efforts of a group of investigators at the University of California, Los Angeles, Stockholm University, and Uppsala University.

The investigators used a three-dimensional printer to produce a lightweight optical attachment to be used with a standard smartphone camera. More...
The device is able to capture multi-color fluorescence and bright-field images of the same quality as those obtained by traditional light microscopy.

The device analyzes a tissue or cell sample in a dedicated container by recording multi-mode images of the sample during processing and feeding the data to an algorithm. The algorithm automatically analyzes the images to read the sequenced bases of the extracted tumor DNA and identifies genetic mutations directly inside the tumor tissue.

“It is very important to have these molecular testing approaches at a doctor’s office or where care is being given,” said senior author Dr. Mats Nilsson, professor of biochemistry and biophysics at Stockholm and Uppsala Universities. “Oftentimes, advanced lab-based testing is performed at major hospitals, which is limiting, as not everyone has access to a hospital that can perform these tests.”

The device was described in detail in the January 17, 2017, online edition of the journal Nature Communications.


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.